High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

Christophe Massard, Stefan Michiels, Charles Ferté, +30

Cancer Discovery

Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

Roberto Ferrara, Laura Mezquita, Matthieu Texier, +25

JAMA Oncology

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

Josep Tabernero, Rastislav Bahleda, Rodrigo Dienstmann, +16

Journal of Clinical Oncology

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria

Mélodie Tazdait, Laura Mezquita, J. Lahmar, +10

European Journal of Cancer

OncologyMedicineRecist 1.1Metastatic NsclcImmune Checkpoint Inhibitor +4

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, +20

Nature Medicine

Outcome of Patients with Non–Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors

Lizza Hendriks, Clémence Henon, Édouard Auclin, +20

Journal of Thoracic Oncology

Neuro-oncologyCheckpoint InhibitorsMedicineImmune Checkpoint InhibitorBrain Metastases Treated +7

Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)

Frédéric Bigot, Eduardo Castañón, Capucine Baldini, +15

European Journal of Cancer

Prognostic EvaluationAutoimmune DiseaseImmunotherapy PhaseImmunodeficienciesPrognosis +8

Osimertinib benefit inEGFR-mutant NSCLC patients withT790M-mutation detected by circulating tumour DNA

Jordi Remón, Caroline Caramella, Cécile Jovelet, +16

Annals of Oncology

OncologyTumour DnaSomatic VariantOncogenic AgentMedicine +5

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

Gonzalo Recondo, Laura Mezquita, Francesco Facchinetti, +38

Clinical Cancer Research

Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation

Marie-Léa Gauci, Émilie Lanoy, Stéphane Champiat, +16

Clinical Cancer Research